ImmuCell CorporationICCCNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank67
5Y CAGR-12.4%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
-12.4%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 48.52% |
| Q3 2025 | -222.83% |
| Q2 2025 | 16.19% |
| Q1 2025 | 724.68% |
| Q4 2024 | 72.62% |
| Q3 2024 | -254.50% |
| Q2 2024 | 35.30% |
| Q1 2024 | 143.28% |
| Q4 2023 | 13.34% |
| Q3 2023 | 33.21% |
| Q2 2023 | 59.64% |
| Q1 2023 | -23.53% |
| Q4 2022 | -39.94% |
| Q3 2022 | -249.64% |
| Q2 2022 | -237.26% |
| Q1 2022 | -44.78% |
| Q4 2021 | 71.97% |
| Q3 2021 | -180.40% |
| Q2 2021 | 84.74% |
| Q1 2021 | -657.50% |
| Q4 2020 | 94.00% |
| Q3 2020 | -2192.07% |
| Q2 2020 | 76.34% |
| Q1 2020 | 46.52% |
| Q4 2019 | -58.28% |
| Q3 2019 | -6.85% |
| Q2 2019 | -190.39% |
| Q1 2019 | 303.63% |
| Q4 2018 | 67.16% |
| Q3 2018 | -50.17% |
| Q2 2018 | 50.11% |
| Q1 2018 | 77.85% |
| Q4 2017 | 7.73% |
| Q3 2017 | -22.80% |
| Q2 2017 | -4.28% |
| Q1 2017 | -70.14% |
| Q4 2016 | -77.15% |
| Q3 2016 | -865.53% |
| Q2 2016 | 68.27% |
| Q1 2016 | -240.85% |